TET2 as a Tumor Suppressor and Therapeutic Target in T-cell Acute Lymphoblastic Leukemia

Investigators analyzed RNA-sequencing data of 321 primary T-cell acute lymphoblastic leukemias (T-ALLs), 20 T-ALL cell lines, and 25 normal human tissues, revealing that TET2 was transcriptionally repressed or silenced in 71% and 17% of T-ALL, respectively.